December 17, 2021
Here are the voting results of the Company’s 2021 Annual General Special Meeting on December 16, 2021 in Vancouver, British Columbia.
November 29, 2021
LexaGene Intends to Pursue Full Panel Pathogen Testing through the FDA
November 15, 2021
Dr. Jane Sykes, BVSc(Hons), PhD, MBA, DipACVIM (Small Animal Internal Medicine) has joined the LexaGene Board of Directors.
Dr. Sykes is the Executive Director of Innovation and Entrepreneurship, School of Veterinary Medicine at the University of California, Davis (UC Davis) and Professor of Small Animal Internal Medicine (Infectious Diseases).
November 9, 2021
today announced it has successfully expanded its bio-pharmaceutical (“bio-pharma”) contamination panel by developing a Burkholderia[i] test for use on its MiQLab™ System.
Burkholderia cepacia complex, a group of about 24 related environmental bacteria, is a problem contaminant for the bio-pharma industry
November 2, 2021
BEVERLY, Mass. USA – October 26, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an…
November 1, 2021
BEVERLY, Mass. USA – October 26, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an…
October 29, 2021
BEVERLY, Mass. USA – October 26, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an…
October 27, 2021
BEVERLY, Mass. USA – October 26, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument…
October 26, 2021
BEVERLY, Mass. USA – October 26, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument…
October 25, 2021
BEVERLY, Mass. USA – October 25, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument…
For Marketing inquiries, please email:
info@lexagene.com
800-215-1824